É um câncer que surge nas células do fígado. Esse tipo de câncer de fígado é relativamente raro nos Estados Unidos, mas muito comum em todos os países da África ao sul do Saara e no Sudeste Asiático. A maioria dos casos é vista em pessoas com mais de 50 anos, mas esse tumor também pode ocorrer em indivíduos mais jovens e até em crianças. É mais comum em homens do que em mulheres e está associado à hepatite B, hepatite C, ao uso abusivo e crônico de álcool e à cirrose (uma doença grave do fígado). Um aumento nos níveis de alfa-fetoproteína no sangue ocorre em uma grande porcentagem dos pacientes com carcinoma hepatocelular. Quando visto a olho nu, o carcinoma hepatocelular pode se apresentar como uma única massa, como múltiplos nódulos (caroços) ou como um envolvimento mais espalhado e difuso no fígado. Ao microscópio, as células dos tumores variam bastante em sua diferenciação (ou seja, o quanto elas se parecem com as células normais do fígado, indo de 'bem diferenciadas' a 'pouco diferenciadas'). Os carcinomas hepatocelulares rapidamente se espalham (formam metástases) para os gânglios linfáticos próximos e para o pulmão. O tempo médio de sobrevida para o câncer de fígado não tratado é de cerca de 4 meses. O tratamento mais eficaz para o carcinoma hepatocelular é a remoção completa do tumor por cirurgia. Recentemente, um número crescente de tumores tem sido tratado com transplante de fígado.
Introdução
O que você precisa saber de cara
O carcinoma hepatocelular é o tipo de câncer que se forma diretamente nas células do fígado, sendo mais comum a partir dos 50 anos de idade. Ele está frequentemente associado à cirrose hepática, ao consumo crônico de álcool e a infecções pelas hepatites B e C. As pessoas afetadas podem sentir dor na região da barriga e do estômago, vômitos, cansaço extremo e apresentar inchaço no fígado. A cirurgia de retirada do tumor ou o transplante são os tratamentos com maior eficácia documentada, enquanto o SUS adota diretrizes onde a medicação é definida conforme a autonomia de cada serviço.
É um câncer que surge nas células do fígado. Esse tipo de câncer de fígado é relativamente raro nos Estados Unidos, mas muito comum em todos os países da África ao sul do Saara e no Sudeste Asiático. A maioria dos casos é vista em pessoas com mais de 50 anos, mas esse tumor também pode ocorrer em indivíduos mais jovens e até em crianças. É mais comum em homens do que em mulheres e está associado à hepatite B, hepatite C, ao uso abusivo e crônico de álcool e à cirrose (uma doença grave do fígado). Um aumento nos níveis de alfa-fetoproteína no sangue ocorre em uma grande porcentagem dos pacientes com carcinoma hepatocelular. Quando visto a olho nu, o carcinoma hepatocelular pode se apresentar como uma única massa, como múltiplos nódulos (caroços) ou como um envolvimento mais espalhado e difuso no fígado. Ao microscópio, as células dos tumores variam bastante em sua diferenciação (ou seja, o quanto elas se parecem com as células normais do fígado, indo de 'bem diferenciadas' a 'pouco diferenciadas'). Os carcinomas hepatocelulares rapidamente se espalham (formam metástases) para os gânglios linfáticos próximos e para o pulmão. O tempo médio de sobrevida para o câncer de fígado não tratado é de cerca de 4 meses. O tratamento mais eficaz para o carcinoma hepatocelular é a remoção completa do tumor por cirurgia. Recentemente, um número crescente de tumores tem sido tratado com transplante de fígado.
Tem tratamento?
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 5 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 14 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
14 genes identificados com associação a esta condição. Padrão de herança: Not applicable.
Colorectal cancer
A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history.
Tuberous sclerosis 2
An autosomal dominant multi-system disorder that affects especially the brain, kidneys, heart, and skin. It is characterized by hamartomas (benign overgrowths predominantly of a cell or tissue type that occurs normally in the organ) and hamartias (developmental abnormalities of tissue combination). Clinical manifestations include epilepsy, learning difficulties, behavioral problems, and skin lesions. Seizures can be intractable and premature death can occur from a variety of disease-associated causes.
Tuberous sclerosis 1
An autosomal dominant multi-system disorder that affects especially the brain, kidneys, heart, and skin. It is characterized by hamartomas (benign overgrowths predominantly of a cell or tissue type that occurs normally in the organ) and hamartias (developmental abnormalities of tissue combination). Clinical manifestations include epilepsy, learning difficulties, behavioral problems, and skin lesions. Seizures can be intractable and premature death can occur from a variety of disease-associated causes.
Familial adenomatous polyposis 1
An autosomal dominant cancer predisposition syndrome characterized by adenomatous polyps of the colon and rectum, but also of upper gastrointestinal tract (ampullary, duodenal and gastric adenomas). This is a viciously premalignant disease with one or more polyps progressing through dysplasia to malignancy in untreated gene carriers with a median age at diagnosis of 40 years.
Caspase-8 deficiency
Disorder resembling autoimmune lymphoproliferative syndrome (ALPS). It is characterized by lymphadenopathy, splenomegaly, and defective CD95-induced apoptosis of peripheral blood lymphocytes (PBLs). It leads to defects in activation of T-lymphocytes, B-lymphocytes, and natural killer cells leading to immunodeficiency characterized by recurrent sinopulmonary and herpes simplex virus infections and poor responses to immunization.
Hepatocellular carcinoma
A primary malignant neoplasm of epithelial liver cells. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes.
Hypomagnesemia 4
A disorder characterized by massive renal hypomagnesemia and normal levels of serum calcium and calcium excretion. Clinical features include seizures, mild-to moderate psychomotor retardation, and brisk tendon reflexes.
Colorectal cancer
A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history.
Primary pigmented nodular adrenocortical disease 4
A rare bilateral adrenal defect causing ACTH-independent Cushing syndrome. Macroscopic appearance of the adrenals is characteristic with small pigmented micronodules observed in the cortex. Adrenal glands show overall normal size and weight, and multiple small yellow-to-dark brown nodules surrounded by a cortex with a uniform appearance. Microscopically, there are moderate diffuse cortical hyperplasia with mostly nonpigmented nodules, multiple capsular deficits and massive circumscribed and infiltrating extra-adrenal cortical excrescences with micronodules. Clinical manifestations of Cushing syndrome include facial and truncal obesity, abdominal striae, muscular weakness, osteoporosis, arterial hypertension, diabetes.
Medicamentos aprovados (FDA)
4 medicamentos encontrados nos registros da FDA americana.
Variantes genéticas (ClinVar)
1.991 variantes patogênicas registradas no ClinVar.
Vias biológicas (Reactome)
200 vias biológicas associadas aos genes desta condição.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Carcinoma hepatocelular
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
Com ensaio aberto em 61 países. O ponto verde marca onde há vaga agora.
🟢 Recrutando agora
100 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
Publicações mais relevantes
Mostrando amostra de 200 publicações de um total de 91.026
Managing Advanced Fibrolamellar Carcinoma at Stage IV: A Case Report.
Fibrolamellar carcinoma (FLC) is a rare primary liver malignancy that predominantly affects young individuals without underlying liver disease, distinguishing it from typical hepatocellular carcinoma. It is characterized by the DNAJB1-PRKACA fusion gene, which is believed to drive tumorigenesis. The diagnosis is often delayed due to nonspecific symptoms. Disease stage and resectability are the most significant prognostic factors. Surgery remains the only potentially curative option, but many patients present with unresectable or metastatic disease, for which there is no established standard treatment. For unresectable and metastatic disease, treatment decisions are largely empirical and based on case series. We report a case of a 29-year-old woman diagnosed with metastatic FLC who was treated with 6 cycles of gemcitabine + oxaliplatin, achieving stable disease for nearly 1 year. However, she subsequently experienced disease progression and rapidly declined, preventing the initiation of further systemic therapy. This case highlights the limitations of current systemic therapies and the urgent need for novel targeted treatments. Further research is essential to improve outcomes for patients with metastatic FLC. O carcinoma fibrolamelar é uma neoplasia maligna primária do fígado rara que afeta predominantemente indivíduos jovens sem doença hepática prévia, distinguindo-se do carcinoma hepatocelular típico. É caracterizado pela fusão dos genes DNAJB1-PRKACA, fator determinante na carcinogénese. Os sintomas são inespecíficos, motivo pelo qual o diagnóstico é frequentemente tardio. O estádio da doença e a possibilidade de ressecção cirúrgica constituem os principais fatores prognósticos. Embora a cirurgia seja a única opção terapêutica potencialmente curativa, muitos doentes apresentam-se com doença irressecável ou metastática ao diagnóstico. Nestes casos, não há tratamento padrão estabelecido, e as decisões terapêuticas são, em grande parte, empíricas e baseadas em séries de casos. Reportamos o caso de uma mulher de 29 anos diagnosticada com carcinoma fibrolamelar metastático, tratada com seis ciclos de gemcitabina + oxaliplatina (GEMOX), com estabilização da doença por quase um ano. Posteriormente, a doente evoluiu com progressão da doença e declínio clínico rápido, impossibilitando a realização de uma nova linha terapêutica. Este caso evidencia as limitações do tratamento sistémico atual e sublinha a necessidade urgente de terapêuticas inovadoras para melhorar os desfechos clínicos em doentes com carcinoma fibrolamelar metastático.
Real-World Analysis of Multidisciplinary Roles in the Management of Hepatocellular Carcinoma: The Mayo Clinic Experience.
Hepatocellular carcinoma (HCC) is a complex disease best managed through multidisciplinary care, yet real-world patterns of medical specialty involvement remain poorly characterized. This study mapped specialty care pathways for HCC patients treated at the three Mayo Clinic destination medical centers. A retrospective review was performed using the Mayo Data Explorer for treatments delivered between May 2020 and May 2025. Patients with HCC were identified through diagnosis codes or hepatology consultation. Therapeutic events across interventional radiology (IR), medical oncology, transplant surgery, radiation oncology, and hepatopancreatobiliary surgery (HPBS) were analyzed descriptively by treatment line and Barcelona Clinic Liver Cancer (BCLC) stage. Of 6051 HCC patients identified, 4799 met inclusion criteria. Hepatology provided consultation for 87% of patients (n=4183). For first-line treatments (n=3079), 37% received initial therapy from IR, 27% from medical oncology, 17% from transplant surgery, 10% from HPBS, and 9% from radiation oncology. IR remained the most common provider across subsequent treatment lines. Analyses were based on treatment events, and some patients contributed to multiple treatment lines. Among patients with documented BCLC stage (n = 906), IR most frequently delivered initial therapy for stages 0 and A, whereas medical oncology predominated for stages B and C. Locoregional therapies were used in 27% of BCLC C patients. This real-world mapping reveals IR as a procedural cornerstone within multidisciplinary HCC management, particularly for early-stage disease. Hepatology remains essential for initial patient evaluation and care coordination. Medical oncology predominates for intermediate-stage disease, while locoregional therapy continues to be used in a substantial proportion of advanced-stage cases. These findings highlight the complex and evolving role of subspecialties in the management of HCC and may inform future resource allocation and care strategies.
Integrative Single-Cell and Spatial Transcriptomic Analysis Reveals MAIT Cell Dysfunction in Relapsed HCC.
Hepatocellular carcinoma (HCC) frequently recurs after curative treatment, and the tumor immune microenvironment plays an important role in disease progression. However, the role of mucosal-associated invariant T (MAIT) cells in relapsed HCC remains poorly understood. This study aimed to characterize transcriptional and spatial features of MAIT cells in relapsed HCC and their association with malignant hepatocyte phenotypes. Tumor samples from primary (n = 3) and relapsed (n = 2) HCC patients were analyzed using paired single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics. scRNA-seq data (49,229 cells) were processed using Seurat with standard quality-control thresholds, followed by Harmony batch correction and unsupervised clustering. Malignant hepatocytes were identified by copy-number variation inference. Spatial transcriptomic data from 35 regions of interest were normalized and deconvolved using scRNA-seq-derived reference profiles. Independent validation was performed using a public HCC scRNA-seq dataset.1. Integrated analyses revealed distinct tumor microenvironmental features in relapsed HCC. Relapsed tumors showed increased representation of malignant hepatocytes with elevated cancer stemness-related transcriptional signatures compared with primary tumors (1.18-fold increase, p < 0.0001), which was spatially supported by enrichment in tumor regions (1.10-fold increase, p ≤ 0.05). Within the T/NK compartment, MAIT cells were significantly enriched in relapsed tumor regions (2.71-fold increase, p ≤ 0.05). Transcriptomic profiling identified distinct MAIT cell states between primary and relapsed HCC, with relapsed MAIT cells displaying dysfunctional phenotype. Cell-cell interaction analysis suggested enhanced ligand-receptor interactions between MAIT cells and malignant hepatocytes in relapsed tumors. In the TCGA LIHC cohort, high relapsed MAIT cell signature scores were associated with poorer overall survival (HR = 1.52, p ≤ 0.05). Relapsed HCC is characterized by enhanced malignant hepatocyte stemness and altered MAIT cell states within the tumor microenvironment. These findings suggest an association between MAIT cell dysregulation and relapse-specific tumor biology, warranting further functional investigation.
Notch signaling in liver diseases: mechanistic insights and therapeutic implications.
The Notch signaling pathway represents an evolutionarily conserved mechanism of intercellular communication that plays critical roles in organ development and tissue homeostasis. However, its functions in liver physiology and pathology demonstrate remarkable context-dependent characteristics, with dysregulated signaling contributing to various liver disorders. This review systematically summarizes the complex roles of Notch signaling in liver health and disease. It comprehensively examines the pathway's essential functions in biliary development, hepatic regeneration, and metabolic homeostasis, while providing a detailed analysis of its pathogenic mechanisms in conditions including Alagille syndrome, drug-induced liver injury, non-alcoholic fatty liver disease, liver fibrosis, hepatocellular carcinoma, and intrahepatic cholangiocarcinoma. Our review particularly emphasizes the dual function of Notch signaling in hepatobiliary malignancies, where it can exert either oncogenic or tumor-suppressive effects depending on specific cellular contexts, molecular interactions, and microenvironmental cues. Furthermore, we highlight the evolution of therapeutic strategies from broad-spectrum γ-secretase inhibitors to more precise approaches involving ligand-specific antibodies, transcriptional complex blockers, and pathway agonists, while addressing persistent challenges in clinical translation including on-target toxicities, compensatory resistance mechanisms, and context-dependent responses. Looking forward, this review outlines promising research directions featuring biomarker-guided patient stratification, rational combination therapies with immune checkpoint inhibitors, and spatiotemporally precise regulatory strategies. By integrating foundational knowledge with recent advances, this work provides valuable insights for understanding Notch signaling's complex roles in liver pathophysiology and for developing novel therapeutic interventions.
A report from the Second Tanzania Liver Cancer Conference (TLCC) 2025 - leading the fight against liver cancer in Sub-Saharan Africa.
The Second Tanzania Liver Cancer Conference (TLCC) took place on 25-26 July 2025 in Dar es Salaam, Tanzania with the aim of uniting healthcare providers to continue the fight against liver cancer in Tanzania. The conference focused on the following agenda items: 1) To build awareness among local and international healthcare providers on the status of liver cancer in Tanzania, and the diagnostic and management options afforded to them. 2) To promote a multidisciplinary approach to the clinical care of patients with liver cancer in Tanzania. 3) To foster local and international collaboration in liver cancer research and care. TLCC 2025 was preceded by community-facing pre-conference activities, including hepatitis B virus screening and vaccination, research network symposium and 2 day surgical camp. The conference was attended by 247 healthcare professionals from varying disciplines, featuring 38 local and international speakers who comprehensively covered a wide range of topics related to research and clinical care of liver cancer patients. Overall, the conference was well-received by attendees. As Tanzania's second conference on the subject, TLCC 2025 marked continuing efforts to lead the fight against liver cancer in Sub-Saharan Africa.
Publicações recentes
Lactate-driven pyrimidine synthesis promotes ferroptosis resistance in hepatocellular carcinoma.
🥉 Relato de casoOncolytic virus therapy for hepatocellular carcinoma: A bibliometric analysis of research landscapes, hotspots, and clinical transformation trends from 2000 to mid-2025.
Extracellular Vesicle-Transferred ATP-Citrate Lyase Induces Monocyte Differentiation Toward Tumor-Associated Macrophages and Fuels Hepatocellular Carcinoma Progression.
🥈 Observacional📚 EuropePMC93.455 artigos no totalmostrando 191
Ononin Inhibits the Growth and Metastasis of Hepatocellular Carcinoma by Suppressing MMP-2 and MMP-9 via PI3K/AKT/mTOR Signaling.
Journal of biochemical and molecular toxicologySix-Transmembrane Epithelial Antigen of the Prostate 1 Promotes HCC Proliferation and Metastasis in vitro and in vivo via the Wnt/β-Catenin Signaling Pathway.
Cancer management and researchOutcomes of transarterial chemoembolization plus percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma with tumor diameter > 3 cm versus ≤ 3 cm: a single-center retrospective study.
Frontiers in oncologyManaging Advanced Fibrolamellar Carcinoma at Stage IV: A Case Report.
GE Portuguese journal of gastroenterologyHepatic Artery Embolization Reduces Tumor-infiltrating-CD8-positive Lymphocytes in an Orthotopic Rat Hepatocellular Carcinoma Model.
Interventional radiology (Higashimatsuyama-shi (Japan)Innovation of a Repeatable Microcatheter-accessible Port (ReMAP): Initial Clinical Results Evaluating Feasibility in the Treatment of Hepatocellular Carcinoma.
Interventional radiology (Higashimatsuyama-shi (Japan)Real-World Analysis of Multidisciplinary Roles in the Management of Hepatocellular Carcinoma: The Mayo Clinic Experience.
Journal of hepatocellular carcinomaIntegrative Single-Cell and Spatial Transcriptomic Analysis Reveals MAIT Cell Dysfunction in Relapsed HCC.
Journal of hepatocellular carcinomaNotch signaling in liver diseases: mechanistic insights and therapeutic implications.
Frontiers in cell and developmental biologyResolution of Hepatitis Delta Virus-Related Cryoglobulinemic Vasculitis With the Use of Bulevirtide.
ACG case reports journalExosomes Regulate Liver Diseases Through the TGF-β1/Smads Signaling Pathway and the Intervention of Traditional Chinese Medicine: A Narrative Review.
Journal of inflammation researchSkeletal muscle index at the third lumbar vertebra/BMI are positively associated with 1-year overall survival in male patients with hepatocellular carcinoma treated with immune checkpoint inhibitors.
Oncology lettersA report from the Second Tanzania Liver Cancer Conference (TLCC) 2025 - leading the fight against liver cancer in Sub-Saharan Africa.
EcancermedicalscienceGinkgolic acid targets HSPA8 to trigger ferroptosis in hepatocellular carcinoma via chaperone-mediated autophagy-dependent GPX4 degradation.
Pharmaceutical biologyAstragalus Polysaccharide Promotes NLRP3+ Macrophages Polarization via Suppression of OGT in Hepatocellular Carcinoma.
Immunological investigationsGut microbiota-metabolism-immunity axis: a novel perspective of traditional Chinese medicine in hepatocellular carcinoma treatment.
Chinese medicineEfficiency and safety of a guidewire-less approach to superselective transarterial microcatheter procedures in hepatic cancer interventions.
BMC cancerTargeting STE20-type kinase MST3 improves metabolic dysfunction-associated steatohepatitis without affecting hepatocellular carcinoma development in mice.
BMC medicineCelecoxib inhibits COX-2 and initiates YAP-dependent mitochondrial apoptosis via YBX1 shuttling in hepatocellular carcinoma.
Cell communication and signaling : CCSThe effect of prior transarterial chemoembolization on response to immune checkpoint inhibitor treatment in patients with hepatocellular carcinoma.
Clinical and molecular hepatologyPsychosocial impact of false-positive surveillance for hepatocellular carcinoma: a qualitative study.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerFiducial marker placement for hepatocellular carcinoma using magnetic resonance imaging-ultrasound fusion guidance: targeting accuracy and determinants of error (with video).
Journal of medical ultrasonics (2001)Artificial Intelligence in hepatology: A position paper by the Italian Association for the Study of the Liver.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the LiverTargeted inhibition of Nrf2 potentiates antitumor immunity and enhances the efficacy of immunotherapy in hepatocellular carcinoma.
Journal for immunotherapy of cancerDiffusion-derived "Vessel Density" (DDVD) and Slow Diffusion Coefficient (SDC) Signal Features of Mass-forming Intrahepatic Cholangiocarcinoma Compared to Those of Hepatocellular Carcinoma and Liver Metastases: Preliminary Results.
RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der NuklearmedizinThe many pathways driving liver inflammation in MASH.
Cell metabolismManganese-mineralized boric acid-modified bovine serum albumin loaded on metal-organic frameworks as a pH- and GSH-responsive nanozyme for active targeted drug delivery.
Biomaterials advancesUltrasound-triggered doxorubicin targeted delivery for liver cancer treatment: Reduced toxicity and improved efficacy.
PloS oneConversion therapy for advanced hepatocellular carcinoma following complete response to transarterial radioembolization combined with atezolizumab and bevacizumab.
Radiology and oncologyAnalysis of HBV Genome Integration in Patients With HBV-Previously Infected NBNC-HCC.
Hepatology research : the official journal of the Japan Society of HepatologyTechnical and clinical outcomes of microwave ablation for HCC: a single-center retrospective analysis of percutaneous ultrasound-guided, intraoperative ultrasound-guided and CT hepatic arteriography-guided approaches.
La Radiologia medicaThe Safety Standards for Liver Percutaneous Thermal Ablation: A Meta-Analysis of Adverse Events over 15 Years.
RadiologyEnzyme-Targeted Antiproliferative Effects of Novel Indole-Acrylamide Xenobiotics Acting on Cyclooxygenase Pathways.
Journal of xenobioticsLiver-related outcomes in patients with tricuspid regurgitation.
European journal of heart failureMETTL3/m6A-Dependent SERPINE1/VEGFA Axis Mediates Sublethal Heat-Induced Angiogenesis in Hepatocellular Carcinoma.
Mediators of inflammationRoute-Dependent Proteomic Landscape in Mouse Models of Carbon Tetrachloride-Induced Hepatic Fibrosis.
Journal of proteome researchConstruction and Validation of a Predictive Model for Post-TACE Recurrence Risk in Hepatocellular Carcinoma: A Retrospective Cohort Study.
Journal of hepatocellular carcinomaWhen is patient-specific lung shunt fraction necessary in 90Y selective internal radiation therapy of liver cancer?
Radiology advancesImmune Checkpoint Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation: Safety Under an Immunosuppression-Preserving Strategy.
Annals of transplantationUsnic acid induces apoptosis and inhibits cell migration and invasion in hepatocarcinoma cells: in vitro and in silico analysis.
BMC complementary medicine and therapiesSystematic review of cost-effectiveness of Chinese PD-1/PD-L1 inhibitors as first-line treatment for hepatocellular carcinoma.
BMC health services researchA preclinical CT and MRI Liver Imaging Dataset with Anatomical, Functional and Segmentation Data.
Scientific dataTSG101 Promotes SIAH1 Auto-Ubiquitination to Drive Migration and Invasion in Hepatocellular Carcinoma Cells.
Journal of cellular and molecular medicineRisk Prediction of Hepatocellular Carcinoma After Hepatitis B Surface Antigen Seroclearance in Patients With Chronic Hepatitis B.
Alimentary pharmacology & therapeuticsStage-dependent gut microbiome and functional signatures across the liver disease spectrum: an integrative multicohort study.
GutTargeting MSR1+ tumor-associated macrophages enhances the therapeutic efficacy of anti-PD-L1 in Hepatocellular carcinoma by suppressing NF-κB pathway activation.
Cancer lettersIrreversible Electroporation versus Stereotactic Body Radiotherapy for Solitary Hepatocellular Carcinoma ≤ 5 cm: A Multicenter Retrospective Study.
JHEP reports : innovation in hepatologyBLOOD: A fast, customizable, and patient-specific computational framework for assessing whole-body lymphocyte dose, survival, and replenishment after radiotherapy treatments.
Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)Liver resection versus transarterial chemoembolization plus PD-1 inhibitors and lenvatinib for hepatocellular carcinoma with portal vein tumour thrombus.
BJS openPredictive value of Hypotension Prediction Index in liver transplantation: a prospective study.
Minerva anestesiologicaAdjuvant camrelizumab for hepatocellular carcinoma patients with high risk of recurrence after curative hepatectomy: a retrospective multicenter study.
European journal of gastroenterology & hepatologyA habitat radiomics model based on contrast-enhanced MRI for predicting early treatment response to hepatic arterial infusion chemotherapy in patients with unresectable hepatocellular carcinoma.
Cellular oncology (Dordrecht, Netherlands)A case of a patient with advanced HCC with Vp4 on hemodialysis who responded to a multimodality treatment including hepatic arterial infusion, radiation therapy, immunotherapy, and molecular-targeted drugs.
Clinical journal of gastroenterologyCARMN::NOTCH2 Fusion-Positive Malignant Glomus Tumor of the Liver: A Rare Tumor With Review of Literature.
International journal of surgical pathologyScreening of Hepatocellular Carcinoma in Hepatic Cirrhosis Patients by a Novel Blood-Based Multi-Omics Test.
Technology in cancer research & treatmentDNA delivered by lipid nanoparticles induces CD8+ T cell-dependent antitumor responses and enhances anti-PD-L1 therapy.
JCI insightSelinexor enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by regulating the BAX/Bcl-2/PUMA apoptotic pathway and the XPO1/p27 cell cycle pathway.
Frontiers in oncologyDevelopment of a post-treatment prognostic model for hepatocellular carcinoma based on nutritional, immune, and inflammatory scoring systems and REDCap-enabled follow-up.
Frontiers in oncologyRecurrence risk prediction model for hepatitis B virus-associated hepatocellular carcinoma patients: a systematic review and meta-analysis.
Frontiers in oncologyArtificial intelligence-based prognostic modeling of immunoradiotherapy in Barcelona clinic liver cancer stage C hepatocellular carcinoma: a multicenter retrospective study.
Frontiers in oncologyLoss of Ezh2 promotes M2-like macrophage polarization in hepatocellular carcinoma.
iSciencePotential influence of omentin-1 genetic variants on the clinicopathological features of patients with hepatocellular carcinoma.
Journal of CancerRNF216 as a Promising Biomarker for Prognosis, Immunotherapy, and Chemotherapy in LIHC: A Comprehensive Pan-Cancer Analysis and Experimental Validation.
Journal of CancerFAM188B promotes progression of hepatocellular carcinoma by regulating YAP/TAZ via interaction with USP10.
Journal of CancerMZB1 at the ER-immunity interface: from antibody folding to disease vulnerability in autoimmunity, inflammation, and cancer.
Journal of CancerNanomedicine-Driven Modulation of Signaling Pathways in Hepatic Fibrosis.
International journal of nanomedicineThe Dual-Faceted Role of Metal-Based Nanomaterials in Hepatic Fibrosis Therapy.
International journal of nanomedicinePerformance Assessment of μTASWako i50, a New Microfluidic Immunoassay System for Hepatocellular Carcinoma Biomarkers AFP, AFP-L3%, and PIVKA-II.
CureusStudy on the effect of Ursolic acid on liver cancer cells using z-vad-fmk and ROS inhibitors.
CytotechnologyMachine Learning Models for Disease-Free Survival Analysis after Liver Resection for Hepatocellular Carcinoma: A Multicentric French Collaborative Study.
Liver cancerComprehensive Evaluation and Validation Reveal Mitochondrial Solute Carrier SLC25A3 as a Novel Prognostic Biomarker and Therapeutic Target in Hepatocellular Carcinoma.
Journal of hepatocellular carcinomaNomogram Using Taurocholic Acid, Age, and Albumin to Predict HBV-Related Cirrhosis/HCC in CHB Patients.
Journal of hepatocellular carcinomaCT-Based Radiomics for Non-Invasive Prediction of Ki-67 Expression in Hepatocellular Carcinoma.
Journal of hepatocellular carcinomaNUP205 Stabilized YAP1 Protein to Stimulate Growth of Hepatocellular Carcinoma Cells in vitro and in vivo.
Journal of hepatocellular carcinomaHCC Is the Predominant Liver-Related Event in MASLD: 2-Step Non-Invasive Algorithms to Stratify Risk in Non-Cirrhotic Patients.
Journal of hepatocellular carcinomaConstruction of a Prognostic Model Based on Insulin Resistance-Related Genes to Predict TACE Response and Identification of PD-98059 as a Potential Therapeutic Agent.
Journal of hepatocellular carcinomaA Case of Microwave Ablation Activating Immune Response in Pulmonary Metastases from Hepatocellular Carcinoma.
Journal of hepatocellular carcinomaLong-term survival and complications of Fontan patients: where do we stand?
American journal of cardiovascular diseaseEvaluation of Anticancer Activity of Novel Sulfanyl-Substituted Hydrazone Compounds in Hepatocellular Carcinoma: In Vitro, In Silico, and In Ovo Studies.
ACS omegaMakorin Ring Finger Protein 1 Inhibits Cell Proliferation in Renal Angiomyolipoma via the ERK/MAPK Signaling Pathway.
Kidney diseases (Basel, Switzerland)Predicting Response to Transarterial Chemoembolization in Hepatocellular Carcinoma Using Machine Learning Models.
The Indian journal of radiology & imagingLiquid biopsy biomarkers for early detection of gastrointestinal cancers: Current landscape and emerging technologies.
Clinical and translational medicinePTTG3P-miR-142-5p-IGF2BP3 axis governs ferroptosis in hepatocellular carcinoma.
Discover oncologyThe APC/C subunit APC7 promotes hepatocellular carcinoma progression by mediating ubiquitination and degradation of LATS1 to activate YAP/TAZ.
Biology directFolate-driven changes in snoRNA function: a novel epigenetic-ribosomal axis in hepatocellular carcinoma.
HereditasIntegrative machine learning analysis suggests novel molecular targets for liver cancer diagnosis and therapy.
Discover oncologyMenopausal hormone therapy and risk of liver cancer in a swedish population-based cohort study.
Journal of the National Cancer InstituteMechanistic investigation of RHEI FLOS extract against hepatocarcinoma via the PI3K/Akt signaling pathway In vitro and Invivo.
Journal of ethnopharmacologyBie-Jia-Jian Pill: Inhibiting tumor glycolysis and promoting CD8+ cell-mediated anti-tumor immunity by targeting HIF-1α-PI3K/AKT/mTOR and CCL20 in hepatocellular carcinoma.
Journal of ethnopharmacologyMolecularly guided therapies for advanced primary liver cancers refractory to systemic treatment: Results from the 2025 French Genomic Medicine Initiative.
Journal of hepatologyEnhancing Prognostication in Hepatocellular Carcinoma Treated With Transarterial Chemoembolization: Beyond Baseline ALBI Grade.
Journal of gastroenterology and hepatologyASO Author Reflections: CT-Based Nested Habitats Analysis for Prognostication of Hepatocellular Carcinoma-Capturing Intratumoral Heterogeneity to Predict Early Recurrence.
Annals of surgical oncologyClinicopathological features and prognosis of dual-phenotype hepatocellular carcinoma after curative hepatectomy: A propensity score matching analysis.
Hepatobiliary & pancreatic diseases international : HBPD INTLocal Tumor Progression After Hepatocellular Carcinoma Ablation: CEUS LI-RADS Nonradiation TRA Version 2024 Versus a Modified Algorithm.
Ultrasound in medicine & biologyAISF practice guidance on pharmacological treatment of metabolic-dysfunction associated steatotic liver disease and steatohepatitis (MASLD/MASH): A 2026 Update.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the LiverOmics insights into MYBL2-promoted cancer stem-like cells driving ferroptosis resistance in hepatocellular carcinoma.
Journal of advanced researchAssociation of nonselective β blockers with the development of hepatocellular carcinoma in liver cirrhosis: a meta-analysis.
Annals of hepatologyExposure to microplastics and liver oncogenesis: A comprehensive review on molecular mechanisms and pathogenic pathways.
ToxicologyAtypical Ductular Reactions Are a Distinct Regenerative Phenomenon in Hepatocellular Carcinoma (HCC) Patients after Transarterial Chemoembolization.
Laboratory investigation; a journal of technical methods and pathologyDental prophylactic Interventions are Associated with Lower Decompensation-related Hospitalizations over 2 years in Cirrhosis.
JHEP reports : innovation in hepatologyMammalian target of rapamycin in chronic liver disease and the potential for therapeutic manipulation.
Experimental gerontologyCorrigendum to "Hellebrigenin induces cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells through inhibition of Akt" [Chemico. Biol. Interact. 219 (2014) 184-194].
Chemico-biological interactionsESM1 drives cancer angiogenesis and bevacizumab resistance via trioleate synthesis.
Neoplasia (New York, N.Y.)Suppression of Indoleamine 2,3-Dioxygenase Enhances Immune Responses to the Therapeutic Vaccine for Chronic Hepatitis B.
Hepatology research : the official journal of the Japan Society of HepatologySuccessful treatment of β-catenin-positive, immune checkpoint inhibitor-resistant tumor in a case of multicentric hepatocellular carcinoma.
Clinical journal of gastroenterologyAugmented reality navigation-assisted laparoscopic radical resection guided by the middle hepatic vein for giant hepatocellular carcinoma in the caudate lobe after neoadjuvant therapy.
Discover oncologyThe prognostic value of peritumoural and intratumoural tertiary lymphoid structures in hepatocellular carcinoma.
Virchows Archiv : an international journal of pathologyTRIM44 as a Multifunctional Regulator in Cancer and Non-Cancer Diseases: From Oncogenic Driver to Immune and Stress Response Modulator.
Protein and peptide lettersLenvatinib combined with immune checkpoint inhibitors for unresectable, recurrent, or metastatic hepatocellular carcinoma: A real-world study.
The oncologistThe Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy.
Hepatology research : the official journal of the Japan Society of HepatologyTACE combined with tislelizumab and lenvatinib in the treatment of intermediate-to-advanced hepatocellular carcinoma: a retrospective real-world study.
BMC cancerProspective Study of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Based on Hepatobiliary Phase of Gd-EOB-DTPA-MRI.
Hepatology research : the official journal of the Japan Society of HepatologyAn endoplasmic reticulum membrane-mimetic GPC3 mRNA nanovaccine for specific immunotherapy of hepatocellular carcinoma.
Communications biologyATGL sensitizes hepatocellular carcinoma cells to genotoxic drugs by modulating p53 acetylation/phosphorylation status.
Cell death discoveryThe Cost-Effectiveness of Universal Hepatitis B Screening in Vietnam.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious DiseasesWho to test and reflex testing for hepatitis D virus infection: evidence and rationale to inform policy recommendations and future directions.
The lancet. Gastroenterology & hepatologyDiscovery of guaianolide-eudesmanolide dimers as antihepatoma agents by targeting NEURL1B to disrupt the DLL1/Notch signaling pathway.
Bioorganic chemistryLong-term outcomes of baseline grey-zone patients with HBeAg-negative chronic hepatitis B virus infection.
JHEP reports : innovation in hepatologyMass spectrometry-based de novo sequencing reveals non-canonical neoantigens with antitumor efficacy in hepatocellular carcinoma.
JHEP reports : innovation in hepatologyLactylation Converts ABHD6 into a Mitochondrial Regulator that Drives Lenvatinib Resistance in Hepatocellular Carcinoma.
Cancer researchHepatocellular Cancer Recurrence After Liver Transplantation With and Without the Use of Intraoperative Blood Salvage and Autotransfusion: A Retrospective Study.
Anesthesia and analgesiaCost-effectiveness of first-line immune checkpoint inhibitor therapies, alone or combined with targeted agents, for unresectable hepatocellular carcinoma in China: an economic evaluation using network meta-analysis.
ImmunotherapyClinical Utility of Deep Learning-based Multiple Arterial Phase MRI in Hepatocellular Carcinoma.
Radiology. Imaging cancerRole of liver X receptors in the pathogenesis and treatment of chronic liver disease (Review).
Molecular medicine reportsTrends in net survival for cancers of the liver and pancreas in Japan, 2000-14 (CONCORD-3).
Japanese journal of clinical oncologyKey mistakes in alcohol-associated liver disease management and how to avoid them: a narrative review.
Expert review of gastroenterology & hepatologyCorrelation Analysis Between Circulating Tumor DNA and Prognosis in Patients with Hepatocellular Carcinoma.
Cancer management and researchTargeting magnesium homeostasis: a novel therapeutic strategy for liver diseases.
Frontiers in nutritionSalvage Resection Following Reassessment of Resectability in Advanced Hepatocellular Carcinoma.
CureusSafety and efficacy of JWATM204, a novel Glypican-3 (GPC3)-targeted CAR T cell therapy for advanced hepatocellular carcinoma: A phase I dose-escalation study.
Cancer pathogenesis and therapyThe Role of Galectin-3 in Liver Inflammation and Fibrosis.
Journal of inflammation researchPredicting the Impact of ARHGAP33 Gene on Liver Cancer Prognosis Based on Multi-Algorithm Model.
International journal of general medicineMarked effect of topical application of Chinese medicine combined with moxibustion in a case of refractory malignant ascites in diffuse liver cancer.
Frontiers in medicineStereotactic body radiotherapy plus lenvatinib and sintilimab with and without transarterial embolization for advanced hepatocellular carcinoma with portal vein tumor thrombus: a dual-center, propensity score-matched retrospective analysis.
Frontiers in immunologyPD-1 blockade does not enhance alloimmunization after allogeneic dendritic cell vaccination in cancer patients.
Frontiers in immunologyAn Inflammation-Associated Prognostic Model for Hepatocellular Carcinoma Following Radical Resection.
Journal of hepatocellular carcinomaEstablishment and Validation of a Nomogram Based on Inflammation-Immunity-Nutrition Biomarker Scores to Predict Postoperative Early Recurrence in Patients with Hepatocellular Carcinoma: A Multicenter Study.
Journal of hepatocellular carcinomaTRIM21 as a Context-Dependent Regulator in Hepatocellular Carcinoma: Integrating Etiological Landscapes (HBV/NASH) with Core Tumor Progression Mechanisms.
Journal of hepatocellular carcinomaA machine learning approach to identify optimal candidates for transarterial chemoembolization in unresectable HBV-related hepatocellular carcinoma complicated by first-branch portal vein tumor thrombus: a multicenter study.
Frontiers in oncologyThe dual regulatory role of METTL14-mediated m6A modification in tumorigenesis and its underlying mechanisms.
Frontiers in oncologyPedunculoside Inhibits Hepatocellular Carcinoma Progression by Activating the MAPK Signaling Pathway Through Targeting and Suppressing CDK4.
Phytotherapy research : PTRUltrasound-Responsive Dual-Prodrug Nanoassembly for "Fenestrae-Restoration Strategy" in Liver Fibrosis Therapy.
Advanced materials (Deerfield Beach, Fla.)Liver Xenotransplantation: Ethical and Societal Implications.
XenotransplantationIdentification and external validation of a prognostic signature based on myeloid-derived suppressor cell-related lncRNAs for hepatocellular carcinoma.
HereditasDiagnostic value of [18F]FAPI-04 PET/CT in patients with monofocal liver lesions suspicious for hepatocellular carcinoma: a prospective comparison with LI-RADS-based contrast-enhanced CT/MRI.
European journal of nuclear medicine and molecular imagingFocal lesions in the cirrhotic liver: an update on LI-RADS classification and clinical implications.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the LiverHypoxia-related and immune phenotype-related fusion model for non-invasive prognostication of hepatocellular carcinoma treated by TACE: a multicentre study.
GutYttrium-90 Transarterial Radioembolization of a Hepatocellular Carcinoma via Parasitized Adrenal and Renal Capsular Arteries.
Journal of vascular and interventional radiology : JVIRKinase signaling in liver disease via clinical-trial-on-a-PamChip: A distinctive methodology for drug mechanisms and personalized medicine.
The Journal of biological chemistryAtezolizumab-Bevacizumab in Very Elderly With Hepatocellular Carcinoma: Age Alone Is Not a Limiting Factor Except in ALBI Grade 3.
JHEP reports : innovation in hepatologyMolecular mechanism of S100P promotes hepatocellular carcinoma by regulating MYBL2-mediated transcription of AURKB.
Cellular signallingDeubiquitination-driven adaptive programs in hepatocellular carcinoma: The emerging role of USP22 in hypoxia, metabolic rewiring, and drug resistance.
GeneProspects for leveraging knowledge on ISG and NF-kB effector functions into anti-HBV therapies.
Antiviral researchThe circadian gene CHRONO drives hepatocellular carcinoma proliferation via G1/S cell cycle transition.
Biochemical and biophysical research communicationsSpatial remodeling of the tumor immune microenvironment in hepatocellular carcinoma with cirrhosis driven by Treg-CD8⁺T cell crosstalk via the SPP1-ITGA4 axis.
Translational oncologyPatterns and predictors of recurrence after curative liver resection for hepatocellular carcinoma: Insights from a single Egyptian center.
American journal of surgerySynthesis and evaluation of Urolithins derivatives as anticancer agents for hepatocellular carcinoma: In vitro, molecular docking, and dynamics simulations.
Bioorganic chemistryBeyond rejection risk: Identifying ideal candidates for Pre-transplant immune checkpoint inhibitors for hepatocellular carcinoma.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation SocietyHepatic Outcomes in Lean Versus Nonlean Metabolic Dysfunction-Associated Steatotic Liver Disease: Propensity-Matched Cohort Study.
Hepatology research : the official journal of the Japan Society of HepatologyCT and MRI LI-RADS Treatment Response Assessment 2024: Core Concepts for Clinical Practice.
Radiographics : a review publication of the Radiological Society of North America, IncCost-Effectiveness Analysis of Anlotinib Plus Penpulimab Versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma in China.
Clinical drug investigationIntegrated in silico and in vitro evaluation of cocoa pod husk as potential anticancer agents against hepatocellular carcinoma.
Molecular biology reportsWho is Afraid of the Gallbladder? Case Series of Unmitigated Pericholecystic Microwave Ablations of Liver Tumours with Pictorial Review.
Cardiovascular and interventional radiologyComputational analysis of multi-omics data reveals CXCL10+ DC-Treg interaction drives immunosuppressive microenvironment in AFP-positive hepatocellular carcinoma.
Cellular and molecular life sciences : CMLSThe correlation between telomere length of the peripheral blood basophil and the risk and prognosis of hepatocellular carcinoma.
Discover oncologyEfficacy of combined laparoscopic hepatectomy and splenic artery ligation for hepatocellular carcinoma with portal hypertension.
Surgery todayDisentangling the Effect of BMI on Hepatocellular Carcinoma From Cirrhosis With Multivariable Mendelian Randomization.
Liver international : official journal of the International Association for the Study of the LiverComparison of diagnostic performance of GAAD, GALAD, and ASAP scores for detecting hepatocellular carcinoma in advanced liver fibrosis patients.
Advances in laboratory medicineGrowth Hormone Pathway as a Prognostic and Therapeutic Biomarker in Patients With Unresectable Hepatocellular Carcinoma Treated With Radiation Therapy.
Advances in radiation oncologyOnce-daily oral ritlecitinib or brepocitinib versus placebo in patients with moderate-to-severely active Crohn's disease (PIZZICATO): an international, randomised, phase 2a trial.
EClinicalMedicineApoptotic body-encapsulated zinc-doped Salvia miltiorrhiza carbon dots trigger PANoptosis for targeted therapy of hepatocellular carcinoma.
Materials today. BioLiver Stiffness Measured by Vibration-Controlled Transient Elastography Predicts Hepatic Decompensation in Patients with Hepatocellular Carcinoma Receiving Systemic Treatments.
Liver cancerPrognostic utility of the serum uric acid-to-high-density lipoprotein cholesterol ratio following hepatectomy for hepatocellular carcinoma.
The Journal of international medical researchImmunogenicity of neoantigens from hepatocellular carcinoma patients treated with a combined radioimmunotherapy.
OncoimmunologyPrussian blue analogue-mineralized ginseng-derived vesicles promote PPARγ nuclear translocation to suppress tumor vasculogenic mimicry and reverse the immunosuppressive microenvironment.
Journal of nanobiotechnologyMulti-omics analysis and experimental validation uncovers prognosis significance of IKBIP in patients with hepatocellular carcinoma: a multicenter cohort study.
BMC gastroenterologyCharacterization and preliminary cytotoxic effects of pomegranate peel extract-loaded nanoparticles on HepG2 cells.
Scientific reportsPractical management of glucagon-like peptide-1 receptor agonists in gastroenterology: a position paper by the Italian Society of Gastroenterology (SIGE).
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the LiverThe ATF5-GPER1 axis drives female protection in hepatocellular carcinoma through dual tumor-suppressive and immune-modulatory mechanisms.
Bioscience trendsCombined Hepatocellular-Cholangiocarcinoma Patient Treated with Durvalumab Plus Gemcitabine and Cisplatin: A Case Report.
Internal medicine (Tokyo, Japan)Token-guided multimodal prognosis in hepatocellular carcinoma: a framework steered by tumour-stroma ratio.
GutThe Odyssey of macrophages.
Biomedical journalDeep-learning-based de novo discovery and design of therapeutics that reverse disease-associated transcriptional phenotypes.
CellpH-regulating Lipiodol Pickering emulsions enhance transarterial embolization therapy via inducing ferroptosis and activating antitumor immunity.
Cell reports. MedicineWDHD1 promotes hepatocellular carcinoma progression by affecting the cell cycle and immune evasion.
Translational oncologyOptimising contrast-enhanced ultrasound (CEUS) Liver Imaging Reporting and Data System (LI-RADS) for hepatocellular carcinoma diagnosis in non-cirrhotic hepatitis B virus infection patients: incorporating alpha-fetoprotein or adjusting washout criteria.
Clinical radiologyHigh-sensitivity detection of alpha-fetoprotein via an unlabelled fluorescent probe based on switchable AIEE effect of a phenolic compound.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopyAnalysis of agreement between radiologists with different levels of CEUS diagnostic experience in CEUSLI-RADS nodule classification: Based on CEUS LI-RADS v2017.
Medical ultrasonographyClinical guideline for the diagnosis and treatment of fibrolamellar carcinoma.
Hepatology (Baltimore, Md.)The role of mesencephalic astrocyte-derived neurotrophic factor in digestive diseases.
Annals of medicineClinical Significance of Anti-Atezolizumab Antibodies in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
Hepatology research : the official journal of the Japan Society of HepatologyAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Carcinoma hepatocelular.
É de uma associação que acompanha esta doença? Fale com a gente →
Doença com base genética
Um médico geneticista pode ajudar no diagnóstico de Carcinoma hepatocelular e no aconselhamento genético da família.
Doenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Perguntas frequentes
O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu
É um câncer primário que tem origem diretamente nas células que formam o fígado. Ele está frequentemente associado à presença de cirrose hepática e a infecções por hepatites virais crônicas.
Referências
Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete
10 publicações do grafo RarasNet (PubMed) · 8 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Citar este verbete
Raras. (s.d.). Carcinoma hepatocelular. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/carcinoma-hepatocelular
Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
Carcinoma hepatocelular
📋 Origem dos dados
Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.
- Doença rara (ontologia)
- fonte: Orphanet
- Identificador unificado
- fonte: MONDO
- Genética mendeliana
- fonte: OMIM
- Codificação WHO/SUS
- fonte: WHO ICD-10 / DATASUS
- CID-11 (futuro)
- fonte: WHO ICD-11
- NIH/GARD
- fonte: GARD (NIH)
- Indexação biomédica
- fonte: MeSH (NLM)
- Dado público estruturado
- fonte: Wikidata
- Medicamentos aprovados FDA
- fonte: FDA OpenFDA
- Reposicionamento
- fonte: Drug Repurposing Hub
- Ensaios clínicos
- fonte: ClinicalTrials.gov
